Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07480928 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Name: Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma — clinical trial record (NCT07480928)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-NK-PDAC

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-02-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Pancreatic Cancer

1,634 trials monitored

See 90 trials at risk

This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and/or MUC1, or (B) Claudin 18.2 (CLDN18.2) and/or MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.

Trial Details

NCT Number	NCT07480928
Lead Sponsor	Beijing Biotech
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
Enrollment	42 participants
Start Date	2026-02-02
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-06-26 (estimated)
Updated on ClinicalTrials.gov	2026-03-18